B019

Phase 1Biologic

SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

B019 is one of 82 biologic programs targeting Lymphoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

B-Cell Acute Lymphoblastic LeukemiaActive, not recruiting

LymphomaPhase 1

Active, not recruiting

B-Cell Acute Lymphoblastic LeukemiaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 2

Velban

EEastern Cooperative Oncology Group

Preclinical

15 3

Oncaspar

SServier

Preclinical

15 4

Nuvigil

NNuvo Research GmbH

Preclinical

1 5

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 6

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

PEG-Intron

1 9

CAR-T

HHebei Senlang Biotechnology Inc., Ltd.

Preclinical

3 10

VP-16

FFundamenta Therapeutics, Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Not yet recruiting

Lymphoma

NCT06970496

Q2 2028

Phase 1Recruiting

B-Cell Acute Lymphoblastic Leukemia

NCT06927466

Clinical

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

Recruiting·SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.·Phase 1·NCT06927466·33 enrolled

Lymphoma1 trial

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Not yet recruiting·SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.·Phase 1·NCT06970496·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for B019. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — B019 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for B019. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.

B019

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2028

Trials by Indication[1]

B-cell acute lymphoblastic leukemia1 trial

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News